Dosage and administration: Usual adult dosage is one tablet daily, between meals, or as directed by a physician or health-care provider. For dialysis patients, Folbee Plus should be taken daily. On dialysis days, Folbee Plus Tablets should be taken after dialysis treatment.

If pregnant, or planning to become pregnant or are currently breast-feeding please contact your physician, or health-care provider before using or continuing use.

Warning: Keep this and all medications out of the reach of children. In case of accidental overdose, seek professional assistance or contact a poison control center immediately.

To report a serious adverse event contact: 1-800-367-3395.

Do not use this product if the inner safety seal under the cap is torn, broken or missing.

This product is recommended for use under the supervision of a physician, or health-care provider.

Contraindications: Known hypersensitivity to any of the components in the products is a contraindication.

Warnings: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient.

Do not exceed recommended dosage.
Precautions: Folic acid when administered as a single agent in doses above 0.1 mg daily, may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. The 1 mg of cyanocobalamin contained in Folbee Plus Tablets has been shown to provide an adequate amount of cyanocobalamin to address this precaution. A safe upper limit of 100 mg per day has been established for the unsupervised medical use of pyridoxine. Consider all sources of pyridoxine supplementation when prescribing Folbee Plus Tablets.

Adverse reactions: Allergic sensitization has been reported following both oral and parenteral administration of folic acid. Paresthesia and somnolence have been reported with pyridoxine hcl. Mild transient diarrhea, polycythemia vera, peripheral vascular thrombosis, itching transitory exanthema and feeling or swelling of entire body has been associated with cyanocobalamin.

Drug interactions: Pyridoxine supplements should not be given to patients receiving the drug levodopa, because the action of levodopa is antagonized by pyridoxine. However, pyridoxine may be used concurrently in patients receiving a preparations containing both carbidopa and levodopa. Concurrent use of phenytoin and folacin (folic acid) may result in decreased phenytoin effectiveness.

Patient information: Folbee Plus Tablets are for use only under the direction and supervision of a licensed physician or health-care provider.

Store at 25(0)C (77(0)F); excursions permitted to 15(0)-30(0)C (59(0)-86(0)F). See USP controlled room temperature. Protect from light and moisture. Dispense in a tight, light-resistant container with a child-resistant closure as defined in the USP/NF.

Sugar and lactose free

Some or all of the following patents may apply:
U.S. Patent No. 4,940,658; U.S. Patent No. 5,563,126; U.S. Patent No. 5,795,873; U.S.Patent No. 6,207,651; U.S. Patent No. 6,297,224; U.S. Patent No. 6,528,496 and other pending patent applications.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.